Relay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the PIK3α inhibitor’s R&D prospects beyond breast cancer.
Relay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the PI3Kα inhibitor’s R&D prospects beyond breast cancer.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders - Relay Ther
Relay drug shows early promise against rare blood vessel diseases
A new ranking of pharma companies by R&D performance
BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026
Amplia takes aim at billion-dollar pancreatic cancer drug market
UCB digs deeper into Bimzelx’s psoriatic arthritis win over Skyrizi
BeOne wins FDA approval in lymphoma race
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy
BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models - BioLine Rx (NASDAQ:BLRX)
BioMarin drug acquired in buyout misses goal in rare disease study
Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with zovegalisib.
While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster…
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
Pfizer and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals.
Maryland drug board to cap price of Ozempic, TrumpRx partners with Cuban, GoodRx, and more biotech news
A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost…
